Transform treatment for immune-mediated diseases, empower people to reimagine their lives.
About Alumis
We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases.
PIPELINE
Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development.
science
We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward.
careers
March 19, 2026 Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 18, 2026 Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
March 2, 2026 Alumis to Present at the Leerink Partners Global Healthcare Conference
More News
